Sharemaestro Newsreel

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market …

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …

Notícias das Ações da Johnson & Johnson (JNJ)

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 …

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?

Cardinal Health CAH is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open. The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1% year-over-year growth. The bottom line estimate is pinned at $2.42, suggesting growth of 16.4%. …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

Leading Women-Run Companies Shaping the Future of Business

An updated edition of the June 17, 2026 article. Corporate leadership is evolving as more women assume top executive roles at publicly traded companies. This transition is increasingly backed by strong business performance, with many women-led organizations delivering innovation, operational excellence and consistent shareholder …

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues …

Rigetti Q2 Earnings Miss Estimates on Higher Costs, Revenue Beat

Rigetti Computing RGTI reported second-quarter 2026 adjusted loss per share of 5 cents, wider than 4 cents in the prior-year quarter. The metric also missed the Zacks Consensus Estimate of earnings by 66.7%. GAAP loss per share in the reported quarter was 16 cents …

Hypera (HYPE3) 2T26: Crescimento de receita e forte geração de caixa

Notícias das Ações da Cooper Companies Inc (COO)

Johnson & Johnson (JNJB34)

Notícias das Ações da BioMarin Pharmaceutical Inc (BMRN)

Notícias das Ações da Universal Health Services Inc (UHS)

Projeções de Resultados: Illumina Inc (ILMN) — LPA e Crescimento de Receita

Projeções de Resultados: Stryker Corp (SYK) — LPA e Crescimento de Receita

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

Projeções de Resultados: Boston Scientific Corp (BSX) — LPA e Crescimento de Receita

Projeções de Resultados: IDEXX Laboratories Inc (IDXX) — LPA e Crescimento de Receita

Projeções de Resultados: Biogen Inc (BIIB) — LPA e Crescimento de Receita

UnitedHealth Stock Rallies 21% on Raised 2026 Guidance. Here’s What Changed

Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.

Panvel (PNVL3): 2T com resultados sólidos

Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.

Hypera Pharma (HYPE3): Resultados em linha, com destaque para a geração de caixa

Projeções de Resultados: Humana Inc (HUM) — LPA e Crescimento de Receita

United Therapeutics: EPS sobe 13% no 2º trimestre fiscal de 2026

Projeções de Resultados: Perrigo Company PLC (PRGO) — LPA e Crescimento de Receita

Projeções de Resultados: Cardinal Health Inc (CAH) — LPA e Crescimento de Receita